Send us a text

This conversation focuses on two issues: (i) identifying the right target MASH patients for Rezdiffra, and (ii) the extensive Madrigal patient support program for Rezdiffra.

It starts with Roger Green asking the group how the current set of target patients is defined. Jeff McIntyre points out that these are the patients currently treated for F2 or F3 MASH in the US healthcare system. Roger asks if this is analogous to the idea of “warehoused” patients observed in Hepatitis C. Jeff suggests these are quite different from warehoused patients in that warehoused patients are not being treated at all, whereas all the target MASH patients are engaged in some form of treatment. 

Next ,Roger notes that Wayne Eskridge published a long post earlier in the day about the extensiveness of the Madrigal patient support program. Wayne discusses the program in some detail, in the process explaining why this process appears likely to be more engaged, interactive and helpful than the typical patient portal program.